Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Oncology
; 70(3): 177-84, 2006.
Article
em En
| MEDLINE
| ID: mdl-16757924
ABSTRACT
OBJECTIVE:
The characteristics and risk factors of the long-term ototoxic effect of cisplatin in testicular cancer patients was studied by measuring distortion product otoacoustic emissions (DPOAEs), which is a highly sensitive, new method for detecting high-frequency hearing loss.METHODS:
223 patients with a median follow-up time of 4.27 years (range 0.5-20 years) and a median age of 37 years (range 18-55 years) were assessed by DPOAE. 100 mg/m2 cisplatin were administered per cycle, in EP, BEP, VeIP, VIP or VPB regimens. The control group consisted of 40 testicular cancer patients without chemotherapy (median age 35 years, range 16-54 years). A detailed medical history evaluated audiological risk factors and hearing complaints. DPOAE was measured in eight frequencies from 750 to 8,000 Hz. Paired t test and Mann-Whitney test were used for statistical evaluation.RESULTS:
Symptomatic ototoxicity was observed in 20% of the patients. In patients receivingCONCLUSION:
DPOAE is a fast, noninvasive and reliable method in detecting late ototoxicity in testicular cancer patients. Contrary to the literature, not only high frequencies are affected. In patients receiving at least 400 mg/m2, using DPOAE we were able to detect significant hearing impairment at lower frequencies that are important for speech perception.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Testiculares
/
Cisplatino
/
Emissões Otoacústicas Espontâneas
/
Audição
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article